Similarly, Lee (46) highlighted the role of NLRP3 as a central driver of chronic neuroinflammation in both AD and Parkinson’s disease and suggested that natural product-derived NLRP3 inhibitors may offer therapeutic benefits. This evidence concerns the gene NLRP3 and Parkinson disease.